Previous research has suggested that patients with metastatic renal cell cancer (mRCC) and bone metastases have a poorer prognosis compared to their counterparts with no skeletal involvement. Therefore, we analyzed the management and outcomes of such patients in our center.
We performed a retrospective study of 35 consecutive patients who received systemic treatment, largely targeted therapy, for mRCC with bone metastases.
The median overall survival was 25 months from the time of diagnosis of mRCC. The 5-year survival rate was 16%. Survival from diagnosis of mRCC was significantly worse in patients with bone metastases present at the start of first-line systemic therapy (median 13 months) compared to delayed metastases diagnosed later during the course of disease (46 months, p=0.01). Few patients (29%) were able to receive more than two lines of systemic therapy. Bone-only metastases were uncommon (11%).
Most patients with mRCC and bone metastases have limited overall survival.
In vivo (Athens, Greece). 0000 Jan [Epub]
Carsten Nieder, Astrid Dalhaug, Adam R Pawinski
Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway ., Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway.